Get the Stockscreener App
5.778
0.34%
-0.042
Profound Medical Corp stock is traded at $5.778, with a volume of 5,000.
It is down -0.34% in the last 24 hours and down -25.40% over the past month.
Profound Medical Corp is a commercial-stage medical device company focused on the development and marketing of AI-powered, MRI-guided, incision-free therapies for the ablation of diseased tissue. The company's flagship product, the TULSA-PRO system, combines real-time MRI, robotically-driven transurethral sweeping action/thermal ultrasound and closed-loop temperature feedback control to ablate whole gland or physician defined region of malignant or benign prostate tissue. Its platform technologies combine imaging, robotic control, and ultrasound-based thermal ablation for the treatment of prostate conditions. The company generates revenue through the sale of capital equipment and recurring sales of single-use devices and related services used in patient treatments.
See More
Previous Close:
$5.82
Open:
$5.68
24h Volume:
5,000
Relative Volume:
0.02
Market Cap:
$208.69M
Revenue:
$16.10M
Net Income/Loss:
$-42.57M
P/E Ratio:
-4.097
EPS:
-1.4103
Net Cash Flow:
$-38.53M
1W Performance:
+12.40%
1M Performance:
-25.40%
6M Performance:
+11.11%
1Y Performance:
-10.77%
1-Day Range:
$5.68
$5.845
1-Week Range:
$5.02
$5.95
52-Week Range:
$3.76
$8.95
Profound Medical Corp Stock (PROF) Company Profile
Name
Profound Medical Corp
Sector
Industry
Phone
647-476-1350
Address
2400 SKYMARK AVENUE, UNIT 6, MISSISSAUGA, ON
Compare PROF vs ABT, SYK, MDT, BSX, EW
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
PROF
Profound Medical Corp
|
5.75 | 211.23M | 16.10M | -42.57M | -38.53M | -1.4103 |
ABT
Abbott Laboratories
|
104.97 | 182.16B | 44.33B | 6.50B | 7.40B | 3.717 |
SYK
Stryker Corp
|
328.95 | 125.39B | 25.12B | 3.25B | 4.28B | 8.3984 |
MDT
Medtronic Plc
|
87.65 | 112.84B | 35.48B | 4.64B | 5.41B | 3.582 |
BSX
Boston Scientific Corp
|
70.19 | 103.71B | 20.08B | 2.89B | 3.66B | 1.9391 |
EW
Edwards Lifesciences Corp
|
82.23 | 48.01B | 6.07B | 1.06B | 1.34B | 1.8063 |
Profound Medical Corp Stock (PROF) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jul-23-24 | Initiated | Lake Street | Buy |
| Jul-16-24 | Upgrade | Stifel | Hold → Buy |
| Nov-28-23 | Initiated | Stifel | Hold |
| Aug-04-23 | Downgrade | Raymond James | Strong Buy → Outperform |
| Mar-21-23 | Downgrade | Jefferies | Buy → Hold |
| Sep-15-20 | Initiated | Jefferies | Buy |
View All
Profound Medical Corp Stock (PROF) Latest News
If You Invested $1,000 in Profound Med Corp (PROF) - Stock Titan
Trading Action: How does Profound Medical Corp perform in inflationary periodsWeekly Trade Recap & Low Drawdown Momentum Trade Ideas - baoquankhu1.vn
Dip Buying: Is Profound Medical Corp showing insider buying2026 Review & Daily Stock Momentum Reports - baoquankhu1.vn
Precision Trading with Profound Medical Corp. (PROF) Risk Zones - Stock Traders Daily
Top 3 Health Care Stocks That Are Set To Fly In March - Benzinga
Returns Recap: Can Profound Medical Corp sustain its profitability2026 Macro Moves & Fast Momentum Stock Entry Tips - baoquankhu1.vn
Profound Medical stock rating reiterated by Raymond James on trial data - Investing.com Australia
Profound Medical reports CAPTAIN trial meets primary safety endpoint - Yahoo Finance
Profound Medical's (PROF) TULSA Procedure Shows Superior Safety Outcomes - GuruFocus
Profound Medical Corp. Reports Results of CAPTAIN Trial Comparing MRI-Guided TULSA Procedure to Robotic Radical Prostatectomy - marketscreener.com
CAPTAIN Trial Comparing Profound's MRI-Guided TULSA Procedure to Robotic Radical Prostatectomy Successfully Meets Primary Safety Endpoint, Preservation of Erectile Function and Urinary Continence - Bitget
Profound Medical Trial Shows TULSA Improves Prostate Cancer Outcomes - TipRanks
Profound Medical (PROF) trial: TULSA tops robotic surgery on key safety outcomes - Stock Titan
Prostate trial: MRI-guided TULSA helps more men keep sex and bladder control - Stock Titan
Aug Outlook: What hedge funds are buying Profound Medical Corp2026 Analyst Calls & Risk Controlled Swing Alerts - baoquankhu1.vn
(PRN) Comprehensive Trading Strategy Report (PRN:CA) - Stock Traders Daily
Profound Medical Announces Board Resignation and New Appointment - TipRanks
Medical Co.'s TULSA-PRO Installed Base Growth & CAPTAIN Trial Data Could Accelerate Adoption in 2026 - Streetwise Reports
Profound Medical to Host Investor Call to Discuss First Clinical Outcomes from the CAPTAIN Trial on March 13; Participate in ROTH Investor Conference on March 22-24 - Investing News Network
Profound Medical to Host Investor Call March 13 on First CAPTAIN Trial Outcomes Presented at EAU 2026 - TradingView
Profound Medical (PROF) Awaits Key Clinical Data Presentation - GuruFocus
Profound Medical to Present First CAPTAIN Trial Results and Steps Up Investor Outreach - TipRanks
(PRN) Technical Pivots with Risk Controls (PRN:CA) - Stock Traders Daily
Profound Medical Corp. (NASDAQ:PROF) Q4 2025 Earnings Call Transcript - Insider Monkey
Profound Medical (TSX:PRN) Narrowing EPS Loss In Q3 2025 Tests Growth Optimism Narrative - simplywall.st
History Review: Can Profound Medical Corp beat the S P 500Market Volume Summary & Fast Entry High Yield Stock Tips - baoquankhu1.vn
Street Watch: Is OVBC forming a bullish divergenceEarnings Performance Report & Verified Swing Trading Watchlist - baoquankhu1.vn
Profound Medical (TSE:PRN) Trading Down 26%Time to Sell? - MarketBeat
Profound Medical reports net loss of USD 8.2M in Q4 2025 - Medical Buyer
Profound Medical (NASDAQ:PROF) Issues Earnings Results - MarketBeat
Profound Medical Corp (PROF) Q4 2025 Earnings Call Highlights: R - GuruFocus
Profound Medical Q4 Earnings Call Highlights - Yahoo Finance
Aug Sentiment: Can Profound Medical Corp beat the S P 500July 2025 Weekly Recap & Stepwise Swing Trade Plans - baoquankhu1.vn
Profound Medical Reports Fourth Quarter and Full Year 2025 Financial Results - Investing News Network
Earnings call transcript: Profound Medical Q4 2025 EPS surprises, stock rises - Investing.com South Africa
Profound Medical (PROF) Reports Q4 Revenue Below Expectations - GuruFocus
Profound Medical (PROF) Reports Q4 Loss, Misses Revenue Estimates - Yahoo Finance
Profound Medical Posts Record Q4 Revenue as TULSA-PRO Adoption and Global Expansion Accelerate - TipRanks
Profound 10-K: Revenue $16.1M, EPS loss $1.41 - TradingView
Profound Medical Corp. Reports Earnings Results for the Full Year Ended December 31, 2025 - marketscreener.com
Profound Medical Q4 Earnings Assessment - Benzinga
Profound Medical Corp. Q4 Profit Climbs - Nasdaq
Profound Medical Brief: Reports Q4 Revenue of US$6.0 Mln, Up From US$4.2 Mln a Year Earlier - marketscreener.com
Profound Medical Brief: Reports a Fourth-Quarter Loss of US$8.2 Mln, or US$0.27 per Share, Compared To a Loss of US$4.9 Mln, or US$0.20 in the Year-Prior Quarter - marketscreener.com
Profound Medical $PROF Shares Purchased by First Eagle Investment Management LLC - MarketBeat
Profound Medical Corp (PROF) Q4 2025 Earnings Call Highlights: Revenue Surge and Strategic ... By GuruFocus - Investing.com Canada
Profound Medical's Earnings: A Preview - Benzinga
Profound Medical Corp (PROF) Q4 2025 Earnings Report Preview: Wh - GuruFocus
(PRN) On The My Stocks Page (PRN:CA) - Stock Traders Daily
Earnings Preview: Profound Medical (PROF) Q4 Earnings Expected to Decline - Finviz
Profound Medical (PROF) Expected to Announce Quarterly Earnings on Thursday - MarketBeat
Profound Medical Corp Stock (PROF) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.00%
0.00%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):